Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Cancer 2Small Cell Lung Cancer Limited Stage 1Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Cholangiocarcinoma 1Brain Neoplasms 1Advanced Cervical Cancer 1

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × anlotinib × Clear all
NCT02825563 2019-05-22

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Completed
22 enrolled

Advanced Cancer

NCT01833923 2015-10-28

ALTN

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Completed
35 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡